# EDGAR Filing Document

**Accession Number:** 0001581178
**File Stem:** 0001171843-26-002448
**Filing Date:** 2026-4
**Character Count:** 5910
**Document Hash:** 85399a25b5eb222f80e249d5cca6eec2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-002448.hdr.sgml**: 20260415

**ACCESSION NUMBER**: 0001171843-26-002448

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260414

**FILED AS OF DATE**: 20260415

**DATE AS OF CHANGE**: 20260414

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EUPRAXIA PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001581178
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41923
- **FILM NUMBER:** 26862126

**BUSINESS ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4
- **BUSINESS PHONE:** 250-590-3968

**MAIL ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of April 2026**

Commission File Number: **001-41923**

**EUPRAXIA PHARMACEUTICALS INC.**

(Exact name of Registrant as specified in its charter)

**N/A** (Translation of Registrant's name)

**201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 Telephone: (250) 590-3968** 

(Address and telephone number of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ X ]

------

**DOCUMENTS INCLUDED AS PART OF THIS REPORT**

---

| | |
|:---|:---|
| **Exhibit** |  |
| [99.1](exh_991.htm) | [Press Release dated April 13, 2026](exh_991.htm) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **EUPRAXIA PHARMACEUTICALS INC.** | **EUPRAXIA PHARMACEUTICALS INC.** |
| Date: April 14, 2026 | By: | <u>/s/ Alex Rothwell</u> |
|  |  | Name: Alex Rothwell |
|  |  | Title: Chief Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences**

VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will present and participate at the following upcoming investor conferences:

**Raymond James Biotech Innovation Symposium**

**Format:** 1x1 Meetings

**Date:** April 14, 2026

**Location:** New York, NY

**2026 Bloom Burton & Co. Healthcare Investor Conference**

**Format:** Presentation & 1x1 Meetings

**Date:** April 21 - 22, 2026

**Presentation Date & Time:** April 21<sup>st</sup> at 11:00AM - 11:30AM ET

**Location:** Toronto, ON

**Webcast link:** https://event.summitcast.com/view/7Mc8ivebFGUgA8YD45rSGK/448mWk34qHYzUoRiwSkQpa

**About Eupraxia Pharmaceuticals Inc.**

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods.

The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.

**For investor and media inquiries, please contact:**

James Meikle, Eupraxia Pharmaceuticals Inc.

236.330.7084 jmeikle@eupraxiapharma.com

or

Kevin Gardner, on behalf of:

Eupraxia Pharmaceuticals Inc.

617.283.2856 kgardner@lifesciadvisors.com

SOURCE Eupraxia Pharmaceuticals Inc.